Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06764836 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors

Name: A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors — clinical trial record (NCT06764836)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Started2024-07-23

View on ClinicalTrials.gov ↗

Record status

This record was last updated January 8, 2025 (before its estimated January 27, 2026 completion). Its status may not reflect the trial's current state.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

10 trials monitored

See all monitored trials

Liver Cancer

1,505 trials monitored

See 60 trials at risk

This study is an open-label, multi-centre, single-arm, phase I clinical study, to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of IMM2510 (an anti-PD-L1/VEGF bispecific antibody fusion protein) + IMM27M (a humanized Fc-engineered anti-CTLA-4 antibody) combination therapy in patients with advanced solid tumors.

Trial Details

NCT Number	NCT06764836
Lead Sponsor	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Conditions	Advanced Solid Tumors, HCC
Enrollment	108 participants
Start Date	2024-07-23
Primary Completion	2026-01-27 (estimated)
Study Completion	2026-01-27 (estimated)
Updated on ClinicalTrials.gov	2025-01-08